Active Ingredient History
Carmustine is a cancer medication that interferes with the growth and spread of cancer cells in the body. Carmustine is used to treat brain tumors, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. A frequent and serious toxicity of BiCNU is delayed myelosuppression. Nausea and vomiting after intravenous administration of BiCNU are noted frequently. Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Astrocytoma (approved 1977)
Ependymoma (approved 1977)
Glioblastoma (approved 1977)
Hodgkin Disease (approved 1977)
Lymphoma, Non-Hodgkin (approved 1977)
Medulloblastoma (approved 1977)
Multiple Myeloma (approved 1977)
Anemia, Aplastic (Phase 2)
Antigens, CD19 (Phase 1/Phase 2)
Antigens, CD20 (Phase 1)
Astrocytoma (Phase 3)
Autoimmune Diseases (Phase 2)
Brain Neoplasms (Phase 3)
BRCA1 Protein (Phase 2)
Breast Neoplasms (Phase 3)
Burkitt Lymphoma (Phase 1/Phase 2)
Cerebellar Diseases (Phase 2)
Chromosome Aberrations (Phase 2)
Colorectal Neoplasms (Phase 2)
Diploidy (Phase 2)
Encephalitis (Phase 2)
Glioblastoma (Phase 3)
Glioma (Phase 3)
Gliosarcoma (Phase 2)
Graft vs Host Disease (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hematologic Diseases (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
HIV (Phase 2)
HIV Infections (Phase 1/Phase 2)
Hodgkin Disease (Phase 2)
Infections (Phase 1/Phase 2)
Intestinal Neoplasms (Phase 2)
Lambert-Eaton Myasthenic Syndrome (Phase 2)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Leukemia, Prolymphocytic (Phase 1/Phase 2)
Leukemia, Prolymphocytic, B-Cell (Phase 2)
Leukemia, Prolymphocytic, T-Cell (Phase 2)
Liver Neoplasms (Phase 2)
Lung Diseases (Phase 3)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 2/Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 3)
Melanoma (Phase 2)
Multiple Myeloma (Phase 3)
Multiple Sclerosis (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Mutation (Phase 2)
Myasthenia Gravis (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasm, Residual (Phase 2)
Neoplasms (Phase 2)
Neuroblastoma (Phase 1)
Neuromyelitis Optica (Phase 2)
Neutropenia (Phase 3)
Oligodendroglioma (Phase 3)
Opsoclonus-Myoclonus Syndrome (Phase 2)
Organ Transplantation (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Peripheral Blood Stem Cell Transplantation (Phase 1/Phase 2)
Plasmablastic Lymphoma (Phase 1/Phase 2)
Prognosis (Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sezary Syndrome (Phase 1/Phase 2)
Stiff-Person Syndrome (Phase 2)
Testicular Neoplasms (Phase 2)
Translocation, Genetic (Phase 2)
Vasculitis, Central Nervous System (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue